newsfilter
← Latest News
GlobeNewswire·

Immutep Quarterly Activities Report Q1 FY26

Media Release Pivotal TACTI-004 (KEYNOTE-F91) Phase III trial evaluating eftilagimod alfa (efti) in first line non-small cell lung cancer continues to build momentum and is recruiting patients at a growing number of